BLOOD COAGULATION FACTOR

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 凝血因子VIII（FVIII）是一种175 kDa的关键止血蛋白，对血液凝固至关重要。FVIII中的天然突变导致轻度至重度A型血友病，这是一种危及生命的血液疾病，影响5000名男性人群中的一人（Wacey等人，1996年）。这种病症的唯一治疗方法是静脉内施用FVIII，其膜结合结构已经由Stoilova-McPhie使用电子显微镜进行了研究（Parmenter和Stoilova-McPhie，2008; Stoilova-McPhie等人，2008年）。 通过冷冻电子显微镜确定膜结合凝血因子Va和因子VIIIa附着于脂质纳米管的结构是该项目的主要目标。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Factor VIII (FVIII) is a key haemostasis protein of 175 kDa, essential for blood clotting. Natural mutations in FVIII result in mild to severe Haemophilia type A, a life-threatening blood condition affecting one in 5000 of the male population (Wacey et al., 1996). The sole cure for this condition is intravenous administration of FVIII, whose membrane-bound structure has been studied by Stoilova-McPhie using electron microscopy (Parmenter and Stoilova-McPhie, 2008; Stoilova-McPhie et al., 2008). Defining the structure of membrane-bound blood coagulation Factor Va and Factor VIIIa attached to lipid nanotubes by Cryo-electron microscopy is the primary goal of this project.